News | News By Subject | News by Disease News By Date | Search News

Multiple myeloma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
This Drug Could be Johnson & Johnson (JNJ)'s Next Billion-Dollar Blockbuster     1/30/2017
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study     12/2/2016
The History Between a Biogen (BIIB) Drug and a High-Profile Democratic Party Fundraiser     10/17/2016
Karyopharm (KPTI) Touts Mid-Stage Data, May See Quicker Approval of Multiple Myeloma Drug     9/6/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon     9/1/2016
Genmab, Inc. (GEN.CO), Johnson & Johnson (JNJ)'s Daratumumab Granted Breakthrough Tag by the FDA     7/26/2016
Amgen (AMGN) Flinches Over Meeting to Review Cost of Multiple Myeloma Drugs     4/7/2016
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement     3/23/2016
Three Drugs Could Catapult Three Big Pharma Revenues This Year     2/9/2016
FDA Grants Full Approval for Amgen (AMGN)'s Blood Cancer Drug     1/25/2016
FDA Approves Takeda (TKPYY)'s Ixazomib for Multiple Myeloma     11/20/2015
Johnson & Johnson (JNJ) Snags Early Approval for Breakthrough Multiple Myeloma Drug Darzalex     11/17/2015
FDA Declines to Approve Spectrum Pharma (SPPI)'s Evomela for Injection     10/23/2015
Three Cancer Drugs are Up for FDA Approval in October     9/28/2015
Karyopharm (KPTI) Tanks After Cancer Drug Trial Patients Get Sepsis     8/10/2015

News from Around the Web
Amgen (AMGN)’s Backup Plan For Kyprolis Flop     9/30/2016
American Society of Hematology: Secondary Cancers Cloud Myeloma Drug, Roswell Park Cancer Institute Study     12/10/2010
High Response Rates Seen In Phase-III Trial Of Chemotherapy, New Drug And Stem Cells In Myeloma, Azienda Ospedaliera Universitaria San Giovanni Battista of Torino Study     10/14/2010
Possible Genetic Links Between Environmental Toxins And Multiple Myeloma, Bank on a Cure(R) Study     8/14/2009
Treatment With Anti-anemia Drugs May Not Be Safe For Multiple Myeloma Patients, American Journal of Hematology     8/15/2008
One Gene May Be Key to Myeloma, National Cancer Institute Researchers Find     6/24/2008
Blocking a Single Protein Proves Toxic to Myeloma Cells in National Institutes of Health (NIH) Studies     6/23/2008
Three-Drug Combination "Extremely Promising" As First-Line Therapy for Multiple Myeloma, Researchers Say     12/14/2007
New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients     12/11/2007
Mayo Clinic: Multiple Myeloma Clinical Trial Shows Distinct Survival Benefit with Lower Dose of Steroids     12/10/2007
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity     12/10/2007
Gene Profiling Can Single Out the Worst Cases of Multiple Myeloma and Guide Therapy     9/19/2007
Emory University Researchers Identify Signaling Protein for Multiple Myeloma     9/11/2007
Potential Therapeutic Targets Identified in Multiple Myeloma     8/14/2007
Mayo Clinic Cancer Center Researcher Finds Mold By-product Kills Multiple Myeloma     4/16/2007

Press Releases
Actinium (ATNM.OB) Announces Pipeline Expansion With Initiation Of Clinical Trial Of Actimab-M In Multiple Myeloma     2/7/2017
Celgene (CELG) Release: Health Canada Approves REVLIMID Plus Dexamethasone As A First-Line Treatment For Patients Newly Diagnosed With Multiple Myeloma, Not Eligible For Transplant     1/24/2017
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma     1/5/2017
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO)     1/5/2017
International Myeloma Foundation Release: Landmark Study Published Today In The Lancet Shows Clear Myeloma Survival Benefit With Triple Drug Combination     12/27/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance     12/20/2016
RedHill Biopharma (RDHL) Announces First Patient Dosed In Phase Ib/II Study With YELIV For Multiple Myeloma     12/19/2016
BioInvent (BOVNF) Terminates Current BI-505 Phase II Study     12/9/2016
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present Initial Results From REO 019 Study In Multiple Myeloma Combining REOLYSIN, Bortezomib And Dexamethasone At The American Society of Hematology Annual Meeting     12/6/2016
Cellectar Biosciences  (CLRB) Presents Poster At The 58th Annual Meeting Of The American Society of Hematology     12/6/2016
Sutro Biopharma ADC Targeting CD74 Exhibits Potent Anti-Tumor Activity In Multiple Malignant Cell Lines And Animal Models Of Non-Hodgkin Lymphoma And Multiple Myeloma     12/6/2016
Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Showed Consistent Clinical Benefit For Previously-Treated Patients With Multiple Myeloma     12/6/2016
Discoveries By GNS Healthcare Causal Machine Learning And Simulation Platform, REFS, Reveal Mechanisms Driving Key Clinical Outcomes In Multiple Myeloma     12/6/2016
Groundbreaking Multiple Myeloma Research Foundation (MMRF) CoMMpass Study(SM) Affirmed As Premier Genomics Data Set In Multiple Myeloma     12/5/2016
Karyopharm (KPTI) Presents Updated Phase IIb STORM Data At The American Society of Hematology 2016 Annual Meeting     12/5/2016

//-->